|
|
|
|
|
|
|
|
Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know
Highlights
- •
- Applications for targeted therapy in gynecologic cancers are growing rapidly.
- •
- Resistance to targeted therapy may be innate, acquired, or adaptive.
- •
- Translational endpoints will be essential to maximize response to targeted therapy.
Abstract
Precision
medicine is a rapidly evolving area in the treatment of gynecologic
malignancies. Advances in sequencing technology have resulted in an
increasing wealth of data regarding the genomic characteristics of
ovarian, endometrial, and cervical cancers. These vast new datasets of
information have led to novel insights into potential vulnerabilities
and therapeutic targets for these cancers. However, unraveling the
complex molecular changes within cancer cells to determine how best to
attack these targets and to identify effective biomarkers of response
remains a significant challenge. In this article, we review the current
status of biomarker-driven targeted therapy in gynecologic malignancies.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.